AMBASARABHAmbalal Sarabhai Enterprises Ltd.

₹34.87-1.33%

Market Cap

₹270.82 Cr

Stock P/E

21.15

ROCE

5.20%

ROE

3.57%

Book Value

₹19.34

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Ambalal Sarabhai Enterprises Ltd. shows moderate growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it has a manageable debt level, it trails behind top performers in revenue growth and efficiency ratios like ROE and ROCE. Companies like Cipla and Dr. Reddy's stand out as leaders in profitability, while Ambalal presents a more cautious investment due to its lower ROE and revenue growth.

Key Points

• Ambalal Sarabhai has a PE ratio of 28.97, indicating it may be overvalued compared to peers with lower PE ratios.
• Revenue growth is modest at 1.93% YoY, significantly lower than many peers which show double-digit growth.
• Debt levels are low at 0.3288, which is favorable compared to peers with higher ratios.

Top Performers

Cipla Ltd.

Highest ROE (16.63%) and significant revenue growth (13.28% YoY), making it a strong performer.

Dr. Reddy's Laboratories Ltd.

Strong profitability metrics with a ROE of 21.76% and low PE ratio (15.50), indicating excellent value.

Mankind Pharma Ltd.

Exceptional revenue growth at 18.12% YoY and strong profitability metrics.